Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

Program: Oral and Poster Abstracts
Type: Oral
Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Rare Lymphoma Subtypes
Monday, December 12, 2011: 6:15 PM

Room 68 (San Diego Convention Center)

Simona Sammassimo1, Giancarlo Pruneri2, Patrick Pileri, MD3, Paola Raffaelli4, Sara Steffano5, Sara Gandini6, Mara Negri7, Thomas H. Habermann8, Zhi-Ming Li9, Pier Luigi Zinzani, MD10, Markus Raderer, MD11, James O. Armitage, MD12, Dennis D Weisenburger, MD13, Donald Barry, MD14, Maria Cabrera15, Emanuele Zucca, MD16, Benedetta Puccin17, Gonzalo Gutierrez-Garcia, MD18, Eva Kalinka-Warzocha18, Andrea Carpaneto19, Caroline Besson20, Elena Porro21, Franco Cavalli, MD22, Grzegorz S. Nowakowski, MD23 and Giovanni Martinelli, MD22

1Haematologyon, European Institute of Oncology, Milan, Italy
2Division of Pathology, European Institute of Oncology, Milan, Italy
3Pathologisches Institut der Universität, Würzburg, Germany
4Unit of Hematopathology, Department of Hematology/Oncology, S.Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
5Pathology, European Institute of Oncology, Milan, Italy
6Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
7Epidemiology and Biostatistic, European Institute of Oncology, Milan, Italy
8Division of Hematology, Mayo Clinic, Rochester, MN
9SUN YAT-SEN UNIVERSITY CANCER CENTER
10Policlinico S. Orsola, Istituto Di Ematologia, Bologna, Italy
11Department of Internal Medicine, Medical University, Vienna, Austria
12Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
13Dept. of Pathology, University of Nebraska Medical Center, Omaha, NE
14Institute of Hematology, Robin Medical Center, Bellinon Hospital, and Sackler Faculty of Medicine, Tel Aviv Univ, Petah Tikva, Israel
15Hospital Salvador, Santiago, Chile
16Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
17Department of Hematology, Hospital Clinic, Barcelona, Spain
18Regional Cancer Center, Lodz, Poland
19Hematology, Ospedale di Roncegno, Roncegno, Italy
20CHU Bicêtre, Université Paris Sud, INSERM U1012, Le Kremlin Bicêtre, France
21Studies Coordination Office, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
22European Institute of Oncology, Milan, Italy

Pulmonary marginal zone lymphoma is a distinct subgroup of B-cell non-Hodgkin’s lymphomas originating from the bronchial-associated lymphoid tissue (BALT) and characterized by an indolent clinical course. Here we present the data of the IELSG-28 study of the International Extranodal Lymphoma Study Group (IELSG) on primary pulmonary lymphoma patients. Clinical records and histological material of 186 patients diagnosed with pulmonary marginal zone lymphoma from December 1986 to June 2009 were collected. The pathology was reviewed centrally and the diagnosis was confirmed in 180 (96%) patients. The median age at diagnosis was 62 (30 - 88). The majority of the patients (149/180) had localized disease at diagnosis with a good performance status (0-1) and low prognostic index (IPI 0-2). Eighty-one patients (45%) received local treatment, including surgery (74%) or radiotherapy (4%). Ninety-nine patients with advanced stage disease or incomplete surgical resection received an additional systemic treatment. Most of these patients (66; 66%) received an alkylating containing regimen, 22 (22%) patients were treated with an anthracycline containing regimen and 29 (29%) received the anti-CD20 monoclonal antibody in combination with chemotherapy. With a median follow up of 67 (range 1 - 256) months, 47/180 patients (26%) experienced disease progression. (median time to progression 30 months, range 0-109). Progression free survival analysis showed a trend in favour of patients treated with immuno-chemotherapy versus those receiving chemotherapy alone (HR 0.53 - 95%CI: 0.21; 1.33), while no difference in terms of OS and PFS was observed between patients receiving systemic anthracycline or alkylating containing regimens. In twenty five cases a specific PCR-assay was carried out for detecting the presence of Achromobacter (Alcaligenes) xylosoxidans. The presence of Achromobacter was detected in 50% of patients.

Our results confirm that local therapy (surgery or radiotherapy) is the treatment of choice for patients with localized disease. Chemotherapy has to be considered in case of relapse, incomplete surgical excision or advanced disease. In this setting, alkylating containing regimens plus rituximab is the most effective option. Further studies are ongoing to confirm the relevance of infection/colonization with Achromobacter (Alcaligenes) xylosoxidans for pathogenesis of BALT lymphoma.

Disclosures: No relevant conflicts of interest to declare.

See more of: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Rare Lymphoma Subtypes
See more of: Oral and Poster Abstracts

* signifies non-member of ASH